Search research articles
Contact Us
Filters
Showing results (471-480 of 497) with videos related to
Page
of 50
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project
Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Cancer
|
April 1, 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
Francesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Cancers
|
July 29, 2023
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
Francesca Palandri, Elena Rossi, Giuseppe Auteri, et al.
Cancers
|
October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Cancer
|
December 21, 2019
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Leukemia
|
August 14, 2024
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands
Erika Tissino, Annalisa Gaglio, Antonella Nicolò, et al.
Cancer
|
December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
Francesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
P Musto, K C Anderson, M Attal, et al.
Leukemia
|
December 21, 2007
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A Palumbo, S V Rajkumar, M A Dimopoulos, et al.
Page
of 50
Search research articles
Search
Showing results (471-480 of 497) with videos related to
Sort By:
Page
of 50
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project
Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Cancer
|
April 1, 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
Francesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Cancers
|
July 29, 2023
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
Francesca Palandri, Elena Rossi, Giuseppe Auteri, et al.
Cancers
|
October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Cancer
|
December 21, 2019
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Leukemia
|
August 14, 2024
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands
Erika Tissino, Annalisa Gaglio, Antonella Nicolò, et al.
Cancer
|
December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
Francesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
P Musto, K C Anderson, M Attal, et al.
Leukemia
|
December 21, 2007
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A Palumbo, S V Rajkumar, M A Dimopoulos, et al.
Page
of 50